The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.

Published on Mar 1, 2019in Chemical & Pharmaceutical Bulletin1.416
· DOI :10.1248/CPB.C18-00744
Takashi Nakada5
Estimated H-index: 5
(Daiichi Sankyo),
Kiyoshi Sugihara4
Estimated H-index: 4
(Daiichi Sankyo)
+ 2 AuthorsToshinori Agatsuma12
Estimated H-index: 12
(Daiichi Sankyo)
: A major limitation of traditional chemotherapy for cancer is dose-limiting toxicity, caused by the exposure of non-tumor cells to cytotoxic agents. Use of molecular targeted drugs, such as specific kinase inhibitors and monoclonal antibodies, is a possible solution to overcome this limitation and has achieved clinical success so far. Use of an antibody-drug conjugate (ADC) is a rational strategy for improving efficacy and reducing systemic adverse events. ADCs use antibodies selectively to deliver a potent cytotoxic agent to tumor cells, thus drastically improving the therapeutic index of chemotherapeutic agents. Lessons learned from clinical failure of early ADCs during the 1980s to 90s have recently led to improvements in ADC technology, and resulted in the approval of four novel ADCs. Nonetheless, further advances in ADC technology are still required to streamline their clinical efficacy and reduce toxicity. [fam-] Trastuzumab deruxtecan (DS-8201a) is a next-generation ADC that satisfies these requirements based on currently available evidence. DS-8201a has several innovative features; a highly potent novel payload with a high drug-to-antibody ratio, good homogeneity, a tumor-selective cleavable linker, stable linker-payload in circulation, and a short systemic half-life cytotoxic agent in vivo; the released cytotoxic payload could exert a bystander effect. With respect to its preclinical profiles, DS-8201a could provide a valuable therapy with a great potential against HER2-expressing cancers in clinical settings. In a phase I trial, DS-8201a showed acceptable safety profiles with potential therapeutic efficacy, with the wide therapeutic index.
Figures & Tables
📖 Papers frequently viewed together
237 Citations
17 Authors (Toshihiko Doi, ..., Kenji Tamura)
145 Citations
17 Authors (Kenji Tamura, ..., Shanu Modi)
113 Citations
#1Hiroji IwataH-Index: 72
#2Kenji TamuraH-Index: 35
Last. Shunji Takahashi (JFCR: Japanese Foundation for Cancer Research)H-Index: 32
view all 18 authors...
2501Background: DS-8201a is a HER2-targeted antibody drug conjugate with novel topoisomerase I inhibitor payload and linker technology. Methods: This ongoing phase 1 study (NCT02564900) enrolls subjects (sbj) with HER2+ breast cancer (BC) post T-DM1, HER2+ gastric cancer (GC) post trastuzumab, HER2 low BC (IHC 1+ or 2+, ISH-), and other HER2-expressing solid tumors (IHC ≥1+). Results: [Results will be updated for presentation at meeting] From Sep 2015–Dec 2017, 212 sbj received ≥1 dose of DS-820...
59 CitationsSource
Cited By71
Abstract null null Antibody-drug conjugates (ADCs) with a drug-to-antibody ratio (DAR) of 8 are attractive as therapeutic anti-cancer agents due to the higher levels of cytotoxic payload delivered to tumors. Biophysical characterization of a DAR 8 ADC fully conjugated at all interchain cysteine residues was carried out to determine if IgG1 interchain disulfide reduction and conjugation led to structural perturbations that impacted product stability. Comparisons between the DAR 8 ADC and the unco...
#1Arielle Medford (Harvard University)H-Index: 5
#2Laura Spring (Harvard University)H-Index: 15
Last. Aditya Bardia (Harvard University)H-Index: 52
view all 4 authors...
The receptor-based classification of breast cancer predicts its optimal therapy. Hormone Receptor (HR) positive breast cancer is treated with endocrine therapy, and HER2+ disease is treated with HER2-targeted therapy. Triple negative breast cancer (TNBC), defined as tumors lacking HR and HER2, represents an aggressive subtype of breast cancer associated with poor prognosis. Development of targeted therapy for this subtype has been challenging since TNBC usually lacks targetable genomic alteratio...
#1Eleanor Watts (University of Texas at Austin)H-Index: 1
#2Gregory K. Potts (AbbVie)H-Index: 1
Last. Jennifer S. Brodbelt (University of Texas at Austin)H-Index: 70
view all 8 authors...
Identifying major histocompatibility complex (MHC) class I immunopeptide antigens represents a key step in the development of immune-based targeted therapeutics and vaccines. However, the complete characterization of these antigens by tandem mass spectrometry remains challenging due to their short sequence length, high degree of hydrophobicity, and/or lack of sufficiently basic amino acids. This study seeks to address the potential for 193 nm ultraviolet photodissociation (UVPD) to improve the a...
#1Zhiyang Cheng (ECNU: East China Normal University)
#2Ying Huang (ECNU: East China Normal University)H-Index: 2
Last. Wei Lu (ECNU: East China Normal University)H-Index: 51
view all 7 authors...
Abstract null null The albumin-based drug delivery system is an effective drug delivery strategy for traditional chemotherapeutic drugs that can improve their antitumour efficacies and reduce systemic toxicities. The camptothecin derivative CPTS0001 has excellent antitumour activity in vitro, but it shows toxicity and side effects in vivo. In this study, we report the synthesis and biological evaluation of the β-glucuronidase-reactive albumin-binding prodrug Mal-glu-CPTS0001 based on quaternary ...
#1Huina Zhang (URMC: University of Rochester Medical Center)H-Index: 22
#2Hani Katerji (URMC: University of Rochester Medical Center)H-Index: 2
Last. David G. Hicks (URMC: University of Rochester Medical Center)H-Index: 69
view all 4 authors...
Objectives null Recent clinical trials have demonstrated significant clinical benefits from novel therapeutic compounds in breast cancer patient with human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) score of 1+ or 2+ and negative in situ hybridization (ISH) result. A new concept of "HER2-low" breast cancer has been proposed and applied in the recent and ongoing clinical trials. In this article, we review the literature on the topic of HER2-low breast cancer. null Methods...
#1Diana Lüftner (Charité)H-Index: 28
#1Carsten Denkert (University Hospital of Giessen and Marburg)H-Index: 98
#2Fenja SeitherH-Index: 5
Last. Christian JackischH-Index: 69
view all 34 authors...
Summary null null Background null The development of anti-HER2 antibody–drug conjugates opens new therapeutic options for patients with breast cancer, including patients with low expression of HER2. To characterise this new breast cancer subtype, we have compared the clinical and molecular characteristics of HER2-low-positive and HER2-zero breast cancer, including response to neoadjuvant chemotherapy and prognosis. null null null Methods null In this pooled analysis of individual patient data, w...
4 CitationsSource
#1Caterina Marchiò (UNITO: University of Turin)H-Index: 36
#2Laura Annaratone (UNITO: University of Turin)H-Index: 21
Last. Anna Sapino (UNITO: University of Turin)H-Index: 69
view all 6 authors...
Abstract The human epidermal growth factor receptor 2 (HER2) is a well-known negative prognostic factor in breast cancer and a target of the monoclonal antibody trastuzumab as well as of other anti-HER2 compounds. Pioneering works on HER2-positive breast cancer in the 90’ launched a new era in clinical research and oncology practice that has reshaped the natural history of this disease. In diagnostic pathology the HER2 status is routinely assessed by using a combination of immunohistochemistry (...
13 CitationsSource
#1Vittoria Perrotti (University of Chieti-Pescara)H-Index: 28
#2Vito Carlo Alberto Caponio (University of Foggia)H-Index: 10
Last. Gianluca Sala (University of Chieti-Pescara)H-Index: 15
view all 8 authors...
Background null Antibody-drug conjugates (ADCs) are designed to deliver potent cytotoxic agents into tumor tissues. During the last two decades, a plethora of ADCs have been successfully developed and used for several indications, including hematologic and solid tumors. In this work, we systematically reviewed the progress in ADC development for the treatment of HNC. null Methods null This review was registered in PROSPERO database. A comprehensive search was conducted following PRISMA guideline...
1 CitationsSource
#1Kamal S. Saini (Covance)H-Index: 17
#2Kevin Punie (Katholieke Universiteit Leuven)H-Index: 10
Last. Sherene Loi (Peter MacCallum Cancer Centre)H-Index: 85
view all 9 authors...
INTRODUCTION : Advanced breast cancer (aBC) remains incurable and the quest for more effective systemic anticancer agents continues. Promising results have led to the FDA approval of three antibody-drug conjugates (ADCs) and two immune checkpoint inhibitors (ICIs) to date for patients with aBC. AREAS COVERED : With the anticipated emergence of newer ADCs and ICIs for patients with several subtypes of breast cancer, and given their potential synergy, their use in combination is of clinical intere...
1 CitationsSource